Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Tuesday, September 7, 1999 Published at 08:11 GMT 09:11 UK


Business: The Company File

GM backlash hits biotech company

Strong public reaction against GM crops has scared away investors

A Cambridge-based biotechnology company has called in the administrators after it was hit by a public backlash against genetically-modified crops.

Food under the microscope
Chief executive of Axis Genetics Mr Iain Cubitt said his company could not raise the £10m funds it needed to keep going as investors were scared off by the adverse publicity surrounding genetically-modified (GM) food. Axis makes vaccines in GM plants.

"Some investors were still wary of getting close to GM plants," Mr Cubitt said.

Axis Genetics has laid off half of its 50 workers, while accountancy firm Ernst & Young continue the search for a new group of investors.

Start-up difficulties

The problem faced by Axis is one not just faced by biotechnology companies, but by many start-up companies in the UK, Dr Malcolm Vanderberg, an independent consultant to the biotechnology industry, said.

"In general the biotechnology industry finds it very hard to raise funds in the United Kingdom, as do a lot of companies who need venture capital," he said.

"They are trying to sell the investor a dream, that they can create something out of nothing and anything that dents that dream has to be bad news," Dr Vanderberg added.

He said that Axis problems were compounded by the "scare of GM food and that would have put some of the investors off because it was something that was going to dent the dream."

The cost of developing an idea from conception to the market place is estimated to be around £300m and many start- up companies underestimate the cost.

"In general, they are going for newer diseases where, not only do they have to discover whether their product works they have to discover how to do research in that particular area," Dr Vanderberg said.



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


The Company File Contents


Relevant Stories

07 Sep 99 | UK
GM expert calls for tougher tests

06 Sep 99 | Wales
Assembly pressure over GM crops ban

04 Sep 99 | UK
GM food 'more worrying than BSE'





Internet Links


Axis Genetics


The BBC is not responsible for the content of external internet sites.




In this section

Microsoft trial mediator welcomed

Vodafone takeover battle heats up

Christmas turkey strike vote

NatWest bid timetable frozen

France faces EU action over electricity

Pace enters US cable heartland

Mannesmann fights back

Storehouse splits up Mothercare and Bhs

The rapid rise of Vodafone

The hidden shopping bills

Europe's top net stock

Safeway faces cash demand probe

Mitchell intervenes to help shipyard

New factory creates 500 jobs

Drugs company announces 300 jobs

BT speeds internet access

ICL creates 1,000 UK jobs

National Power splits in two

NTT to slash workforce

Scoot links up with Vivendi

New freedom for Post Office

Insolvent firms to get breathing space

Airtours profits jump 12%

Freeserve shares surge

LVMH buys UK auction house

Rover - a car firm's troubles